Lacosamide G.L. Pharma Gmbh

Lacosamide, the active ingredient in Lacosamide G.L. Pharma Gmbh, is a sodium channel blocker presented as an oral formulation for oral use. It is employed as adjunctive therapy for partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamide G.L. Pharma Gmbh as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Their distribution network ensures timely delivery and compliance with local regulatory requirements.

Lacosamide is an antiepileptic drug used to treat seizure disorders by modulating neuronal excitability. - Partial-onset seizures: reduces seizure frequency as add‑on therapy. - Focal epilepsy: improves overall seizure control when combined with other antiepileptics. - Adjunctive therapy for epilepsy: enhances treatment efficacy in patients not fully controlled by monotherapy.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue - Diplopia - Somnolence

Serious or Rare Side Effects: - Cardiac arrhythmia - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior - Elevated liver enzymes - Blood dyscrasias - Anaphylactic reactions

When prescribing lacosamide, clinicians should consider several safety aspects to minimize risk. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant CNS depressants: may increase sedation; observe patient response. - Pregnancy: potential risk unknown; discuss benefits and risks with the patient. - Driving and operating machinery: dizziness may impair ability; advise caution. - Store at room temperature: keep in original container, protect from moisture.

Lacosamide can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, decreasing lacosamide plasma levels. - Phenytoin: induces metabolism, reducing lacosamide exposure. - Strong CYP3A4 inducers (e.g., rifampin): may lower lacosamide concentrations.

Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression may increase dizziness or somnolence. - Other antiepileptics (e.g., valproate): may require dose adjustments based on clinical response.